Hyderabad-based Laurus Labs receives licence to manufacture 2DG
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for the treatment of Covid-19 patients in the country.
Hyderabad: Hyderabad-based Laurus Labs, a research & development-driven and fully integrated pharmaceutical and biotech company, has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market 2- Deoxy-D-Glucose (2DG).
2DG has been given emergency approval by the Drug Controller General of India (DCGI) for the treatment of Covid-19 patients in the country. Laurus Labs has already applied with CDSCO for emergency use authorisation (EUA) for 2DG.
Laurus over the years has built its capabilities in the areas of bulk drugs for anti-retroviral (ARV), oncology, cardiovascular, anti-diabetics, anti-asthma, and gastroenterology. The company is also in the formulations space catering to North America, Europe, and Low Middle-Income Countries (LMIC). Its manufacturing facilities are approved by major regulatory authorities such as the USFDA, WHO-Geneva, UK-MHRA, etc.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
